Cctc Natco Exam 2024

Lymphocyte Depleting induction agent - ANSWERSAnti-thymocyte globulin 5-6 mg/kg IV in divided doses 1st dose intraoperatively Alemtuzumab (Campath) 30 mgIV x 1 dose Given introperatively Muromonab (OKT3)anti CD3 monoclonal 5 mg IV daily for 10 days Lymphocyte Non-depleting induction agent reaction - ANSWERSIL2 Simulect (basiliximab) Binds to CD25 on active T lymphocytes Inhibits IL2 mediated T-lymphocytes Kidney/liver top induction Dose 20 mg IV c 2 doses 1st dose Ontario 2 bd dose given on POD4 Leflunomide (Arava) - ANSWERSLymphocyte proliferation 40 mg PO daily May be totrated from 20-100 mg day until BK virus serum PCR undetectable MELD score - ANSWERSNa Serum bilirubin Creatinine INR ProstaglandinE-1 - ANSWERSFree radical inhibition Inhibition of platelet / WBC aggregation Improvement of hepatic micro circulation Inhibitionnof cytokines release Titrationnof BP Reduce post ischemic repercussion injury skin cancer risk factors - ANSWERSCertain meds Variconazole Aziathroprine Ruxolitinib(jakafi) Increase in immunosuppression for organ rejection Age Hx of skin cancer Total body irradiation Low platelet counts Female increased risk Melanoma Males increase risk for NMSC Septic lung disease - ANSWERSFVC less than or equal to 40% Lung eval - ANSWERSPFT's Cxray Exercise studies Rehab VQ scan- how lungs are perfuming Barium swallow Card cath PFT (pulmonary function test) - ANSWERSTLC total lung volume F